Samra Turajlić, Director at CRUK Manchester Institute, shared a post on LinkedIn:
“Thanks to everyone who battled the elements to attend this event at The Francis Crick Institute. It was a very timely moment to give this public crash course in immunotherapy.
The first patients with advanced melanoma I met, exactly 20 years ago, almost invariably died of their disease – I rarely had the chance to really get to know them.
Today, about half of the patients I see in the same situation, treated with combination immunotherapy, will be in remission ten years later. Immunotherapy has also helped reduce the risk of melanoma coming back after surgery for localised disease.
But – what about the patients who don’t benefit? What about the side effects of immunotherapy? And what about other cancers, where immunotherapy works but only for a small number of people?
Solving these challenges so that more people can benefit from these advances is a tall order. That’s why we’ve teamed up with colleagues from different fields and centres across the country to tackle this together in the MANIFEST platform and consortium.”
More posts featuring Samra Turajlić.